^
    6ms
    To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Jemincare
    New P1 trial
    |
    HBI-2438
    9ms
    Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Jemincare
    New P1 trial
    |
    itraconazole • HBI-2438 • midazolam hydrochloride • rifampicin
    2years
    A Phase 1 , Open-Label, Dose Escalation of HBI-2438 in Patients with Advanced Malignant Tumors Harboring KRAS G12C Mutation (ESMO Asia 2022)
    No abstract available
    Clinical • P1 data
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    HBI-2438
    2years
    A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation (clinicaltrials.gov)
    P1, N=44, Recruiting, HUYABIO International, LLC. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    HBI-2438
    over2years
    A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation (clinicaltrials.gov)
    P1, N=44, Not yet recruiting, HUYABIO International, LLC.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    HBI-2438